RT Journal Article
SR Electronic
T1 Prediction of type 2 diabetes mellitus onset using logistic regression-based scoreboards
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.02.20165092
DO 10.1101/2020.08.02.20165092
A1 Edlitz, Yochai
A1 Segal, Eran
YR 2021
UL http://medrxiv.org/content/early/2021/07/03/2020.08.02.20165092.abstract
AB Type 2 diabetes mellitus (T2DM) accounts for ∼90% of all cases of diabetes which are estimated with an annual world death rate of 1.6 million in 2016. Early detection of T2D high-risk patients can reduce the incidence of the disease through a change in lifestyle, diet, or medication. Since populations of lower socio-demographic status are more susceptible to T2D and might have limited resources for laboratory testing, there is a need for accurate yet accessible prediction models based on non-laboratory parameters. This paper introduces one non-laboratory model which is highly accessible to the general population and one highly precise yet simple laboratory model. Both models are provided as an accessible scoreboard form and also as a logistic regression model. We based the models on data from 44,879 non-diabetic, UK Biobank participants, aged 40-65, predicting the risk of T2D onset within the next 7.3 years (SD 2.3). The non-laboratory prediction model for T2DM onset probability incorporated the following covariates: sex, age, weight, height, waist, hips-circumferences, waist-to-hip Ratio (WHR) and Body-Mass Index (BMI). This logistic regression model achieved an Area Under the Receiver Operating Curve (auROC) of 0.82 (0.79-0.85 95% CI) and an odds ratio (OR) between the upper and lower prevalence deciles of x77 (28-98). We further analysed the contribution of laboratory-based parameters and devised a blood-test model based on just five blood tests. In this model, we included age, sex, Glycated Hemoglobin (HbA1c%), reticulocyte count, Gamma Glutamyl-Transferase, Triglycerides, and HDL cholesterol to predict T2D onset. This logistic-regression model achieved an auROC of 0.89 (0.86-0.91) and a deciles’ OR of x87 (27-152). Using the scoreboard results, the Anthropometrics model classified three risk groups, a group with 1%(1-2%); a group with 9% (7-11%) probability, and a group with a 15% (7-23%) risk of developing T2D. The Five blood tests scoreboard model, further classified into four risk groups: 0.9% (0.7%-1%); 8%(6-11%); 18%(14-22%) and a high risk group of 38%(23-54%) of developing T2D. We analysed several more comprehensive models which included genotyping data and other environmental factors and found that it did not provide cost efficient benefits over the five blood tests model. The Five blood tests and anthropometric models, both in their logistic regression form and scoreboard form, outperform the commonly used non-laboratory models, the Finnish Diabetes Risk Score (FINDRISC) and the German Diabetes Risk Score (GDRS). When trained using our data, the FINDRISC achieved an auROC of 0.75 (0.71-0.78), and the GDRS auROC resulted in 0.58 (0.54-0.62), respectively.Competing Interest StatementThe authors have declared no competing interest.Funding StatementE.S. is supported by the Crown Human Genome Center, by D. L. Schwarz, J. N. Halpern and L. Steinberg, and by grants funded by the European Research Council and the Israel Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:01/03/2020 Title of the project: COPY from protocol: 149-1 - Development of models relating genetics, diet, lifestyle, and clinical outcomes (945-1) Submitted by: Eran Segal on 01/03/2020 Dear Eran Segal, This is to certify that Weizmann Institutional Review Board (IRB) reviewed the above research project and approved it for execution at the Weizmann Institute of Science. The certificate of approval expires on 01/03/2023 Sincerely yours Prof. Yosef Shaul, Head Weizmann IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe UKB data are available through the UK Biobank Access Management System https://www.ukbiobank.ac.uk/ https://www.ukbiobank.ac.uk/